收费全文 | 78460篇 |
免费 | 7025篇 |
国内免费 | 3012篇 |
耳鼻咽喉 | 397篇 |
儿科学 | 3860篇 |
妇产科学 | 433篇 |
基础医学 | 7522篇 |
口腔科学 | 2164篇 |
临床医学 | 6335篇 |
内科学 | 11850篇 |
皮肤病学 | 561篇 |
神经病学 | 1847篇 |
特种医学 | 3256篇 |
外国民族医学 | 6篇 |
外科学 | 31458篇 |
综合类 | 8832篇 |
现状与发展 | 14篇 |
一般理论 | 2篇 |
预防医学 | 1761篇 |
眼科学 | 1276篇 |
药学 | 2759篇 |
19篇 | |
中国医学 | 892篇 |
肿瘤学 | 3253篇 |
2024年 | 125篇 |
2023年 | 1019篇 |
2022年 | 1544篇 |
2021年 | 2405篇 |
2020年 | 2405篇 |
2019年 | 2533篇 |
2018年 | 2789篇 |
2017年 | 2494篇 |
2016年 | 2666篇 |
2015年 | 2703篇 |
2014年 | 4511篇 |
2013年 | 5003篇 |
2012年 | 3817篇 |
2011年 | 4622篇 |
2010年 | 4102篇 |
2009年 | 4377篇 |
2008年 | 4403篇 |
2007年 | 4609篇 |
2006年 | 4576篇 |
2005年 | 4194篇 |
2004年 | 3425篇 |
2003年 | 2884篇 |
2002年 | 2266篇 |
2001年 | 1944篇 |
2000年 | 1807篇 |
1999年 | 1398篇 |
1998年 | 1224篇 |
1997年 | 1127篇 |
1996年 | 967篇 |
1995年 | 850篇 |
1994年 | 888篇 |
1993年 | 579篇 |
1992年 | 665篇 |
1991年 | 498篇 |
1990年 | 371篇 |
1989年 | 341篇 |
1988年 | 353篇 |
1987年 | 252篇 |
1986年 | 238篇 |
1985年 | 240篇 |
1984年 | 189篇 |
1983年 | 97篇 |
1982年 | 159篇 |
1981年 | 132篇 |
1980年 | 111篇 |
1979年 | 118篇 |
1978年 | 104篇 |
1977年 | 91篇 |
1976年 | 63篇 |
1973年 | 43篇 |
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献Background and aims
Since accelerated atherosclerosis has been reported in systemic lupus erythematosus (SLE), predictive biomarkers of cardiovascular disease (CVD) are needed. Among non-traditional risk factors, bone mineral density (BMD) has been related to CVD. However, its role in SLE remains controversial. This study aims to analyze the associations of subclinical atherosclerosis with traditional and non-traditional CV risk factors.Methods and results
In a cross-sectional study, atherosclerosis burden was compared between 112 female SLE patients and 31 controls. Plaque number and carotid intima-media wall thickness (cIMT) were assessed by ultrasonography. In a retrospective study, BMD determinations obtained 5-years before the ultrasonography assessment were analyzed in a subgroup of 62 patients. Plaque frequency was increased in SLE, even in patients without CV events or carotid wall thickening. cIMT was increased in patients with CVD, positively correlated with body mass index (BMI). Interestingly, a paradoxical effect of BMI on carotid parameters was observed. Whereas underweight patients (BMI < 20) showed increased prevalence of carotid plaques with low cIMT, those with BMI > 30 showed higher cIMT and plaque burden. Overweight patients (25 < BMI<30) exhibited both elevated cIMT and plaque number. BMI was an independent predictor of BMD. In our retrospective study, patients with either clinical or subclinical CVD exhibited lower BMD levels than their CV-free counterparts. A low lumbar spine BMD independently predicted CVD development after adjusting for confounders.Conclusion
SLE was associated with a higher subclinical atherosclerosis burden, a bimodal effect being observed for BMI. Decreased BMD can be a CV risk biomarker in SLE. 相似文献Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献